ResearchMoz

Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2013-03-13
No. Of Pages » 128
 
   
 Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules...
Table of content

Chapter 1 Introduction
1.1 Report description
1.2 Market segmentation
1.3 Scope of the report
1.4 Research methodology
1.5 Assumptions

Chapter 2 Executive Summary
2.1.1 Global peptide therapeutics market revenues, 2010 – 2018 (USD Million)
2.1.2 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million)
2.1.3 Global API peptide therapeutics market, 2011 (USD Million)
2.1.4 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%)

Chapter 3 Global Peptide Therapeutics Market Dynamics
3.1 Overview
3.2 Drivers
3.2.1 Increase in cancer patient population to propel the growth of new peptides
3.2.2 Rise in metabolic disorders to escalate the growth of peptides market
3.2.3 Rise in R&D pipeline of peptide drugs is expected to bring considerable growth in coming years
3.2.3.1 Global peptide therapeutics trials growth, 1970 - 2011
3.2.4 Technological enhancement has boosted the growth of the market with radical reduction in total production cost of peptides
3.3 Restraints & challenges
3.3.1 Increasing complexity of peptides is a huge challenge for manufacturers
3.3.2 Lack of regulatory standards hampering the growth of the market
3.3.3 Matching equipments with customer requirements is a major challenge for API peptide manufacturers
3.4 Opportunities
3.4.1 Rise in cancer vaccine to drive the future market
3.4.2 Generic peptides market to flourish with patent cliff expected in the forecast period
3.4.3 Small biotech firms collaborating with large pharmaceutical companies to explore further growth
3.4.3.1 Global scenario of acquisitions of biotech firms by large pharma giants
3.4.3.2 Major peptide drugs and sales, 2011 (USD Million)
3.5 Porters five forces analysis
3.5.1 Porter’s five forces analysis of global peptide therapeutics market
3.5.2 Bargaining power of suppliers
3.5.3 Bargaining power of buyers
3.5.4 Threat of new entrants
3.5.5 Threat of substitutes
3.5.6 Competitive rivalry
3.6 Market attractiveness analysis
3.6.1 Market attractiveness analysis of the peptide therapeutics market by geography
3.7 Peptide therapeutics - emerging technologies & trends
3.8 Regulatory policies

Chapter 4 Global Peptide Therapeutics Market Analysis, By Applications
4.1.1 Introduction
4.1.1.1 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million)
4.1.2 Cancer
4.1.2.1 Global cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
4.1.2.2 Global cancer peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.3 Metabolic
4.1.3.1 Global metabolic peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
4.1.3.2 Global metabolic peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.4 Cardiovascular
4.1.4.1 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
4.1.4.2 Global cardiovascular peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.5 Dermatology
4.1.5.1 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012
4.1.5.2 Global dermatology peptides market revenues, 2010 – 2018 (USD Million)
4.1.6 Anti-Infection
4.1.6.1 Global anti-infection drugs analysis, number of trials, 2009 - 2012
4.1.6.2 Global anti-infection peptides market revenues, 2010 – 2018 (USD Million)
4.1.7 Neurology
4.1.7.1 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012
4.1.7.2 Global neurology peptides market revenues, 2010 – 2018 (USD Million)
4.1.8 Gastro Intestinal
4.1.8.1 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012
4.1.8.2 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million)
4.1.9 Renal
4.1.9.1 Global renal pipeline drugs analysis, number of trials, 2009 - 2012
4.1.9.2 Global renal peptides market revenues, 2010 – 2018 (USD Million)
4.1.10 Respiratory
4.1.10.1 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012
4.1.10.2 Global respiratory peptides market revenues, 2010 – 2018 (USD Million)
4.1.11 Pain
4.1.11.1 Global pain pipeline drugs analysis, number of trials, 2009 - 2012
4.1.11.2 Global pain peptides market revenues, 2010 - 2018 (USD Million)
4.1.12 Others
4.1.12.1 Global other pipeline drugs analysis, number of trials, 2009 - 2012
4.1.12.2 Global other peptides market revenues, 2010 – 2018 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.1.1 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018 (USD Million)
5.1.2 Methods of delivery for peptide drugs
5.2 Parenteral Route
5.2.1 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million)
5.3 Oral Route
5.3.1 Global peptide therapeutics market revenues, by oral route of administration, 2010 - 2018 (USD Million)
5.4 Pulmonary Route
5.4.1 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million)
5.5 Mucosal Route
5.5.1 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million)
5.6 Others (Intradermal & Nasal)
5.6.1 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million)

Chapter 6 Peptide Therapeutics Market – Generic & Innovative Segments
6.1 Introduction
6.1.1 Global peptide therapeutics market, by types revenues, 2010 - 2018 (USD million)
6.2 Peptide Therapeutics – Innovative market
6.2.1 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million)
6.3 Peptide Therapeutics – Generic market
6.3.1 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million)

Chapter 7 API Peptide Therapeutics Market, In-house Vs CMO
7.1 Introduction
7.2 API peptide therapeutics – In-house market
7.2.1 Global API peptide therapeutics in-house market revenues, 2010-2018 (USD Million)
7.3 Contract Manufacturing Organizations (CMO)
7.3.1 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million)

Chapter 8 Peptide Therapeutics Market, By Technology
8.1 Introduction
8.1.1 Global peptide therapeutics market revenues, by technology, 2010 – 2018 (USD Million)
8.2 Solid Phase Peptide Synthesis (SPPS)
8.2.1 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.3.1 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million)
8.4 Hybrid Technology
8.4.1 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million)

Chapter 9 Peptide Therapeutics Market, By Geography
9.1 Introduction
9.1.1 Global peptide therapeutics market share, by geography, 2011 - 2018
9.2 North America
9.2.1 North America peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.3 Europe
9.3.1 Europe peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.4 Asia 
9.4.1 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million)
9.5 Rest of World
9.5.1 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million)

Chapter 10 Market Share Analysis
10.1 Market share by key players
10.2 Market share by key players in peptide drugs market
10.2.1 Global peptide therapeutics market share analysis of key players, 2011 (%)
10.3 Market share by key players in CMO segment
10.3.1 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%)

Chapter 11 Recommendations
11.1 Success strategies
11.1.1 Rigorous research and development (R&D) initiatives
11.1.2 Investing in emerging economies
11.1.3 Investing in recent technologies such as HPPS TEchnology
11.1.4 Mergers and acquisitions
11.2 Barriers to be considered
11.2.1 The high cost of peptide synthesis
11.2.2 Weak pipeline peptide drug candidates in phase III

Chapter 12 Company Profiles
12.1 Bachem Holding AG
12.1.1 Company overview
12.1.2 Financial overview
12.1.3 Strategic overview
12.1.3.1 Collaborations
12.1.3.2 Expansion
12.1.3.3 Divestiture
12.1.3.4 Recent developments
12.2 Eli Lilly and Company
12.2.1 Company overview
12.2.2 Financial overview
12.2.3 Strategic overview
12.2.3.1 Agreements
12.2.3.2 Approvals
12.2.4 Recent developments
12.3 Pfizer, Inc.
12.3.1 Company overview
12.3.2 Financial overview
12.3.3 Strategic overview
12.3.3.1 Mergers and acquisitions
12.3.3.2 Divestiture
12.3.3.3 Approvals
12.3.4 Recent developments
12.4 Amgen, Inc.
12.4.1 Company overview
12.4.2 Financial overview
12.4.3 Strategic overview
12.4.3.1 Mergers and acquisitions
12.4.3.2 Licensing
12.4.4 Recent developments
12.5 Takeda Pharmaceutical Company Limited
12.5.1 Company overview
12.5.2 Financial overview
12.5.3 Strategic overview
12.5.3.1 Partnerships and collaborations
12.5.3.2 Mergers and acquisitions
12.5.4 Recent developments
12.6 Teva Pharmaceuticals
12.6.1 Company overview
12.6.2 Financial overview
12.6.3 Strategic overview
12.6.3.1 Mergers and acquisitions
12.6.3.2 Investing in generic and biosimilar segments
12.6.4 Recent developments
12.7 Lonza Inc.
12.7.1 Company overview
12.7.2 Financial overview
12.7.3 Strategic overview
12.7.3.1 Investing in emerging economies
12.7.3.2 Mergers and acquisitions
12.7.4 Recent developments
12.8 Peptisyntha
12.8.1 Company overview
12.8.2 Financial overview
12.8.3 Strategic overview
12.8.3.1 Arranging and participating in trade shows
12.8.3.2 Continuous manufacturing expansion
12.9 Sanofi
12.9.1 Company overview
12.9.2 Financial overview
12.9.3 Strategic overview
12.9.3.1 Acquisitions
12.9.3.2 Divestments
12.9.4 Recent developments
12.10 Ipsen
12.10.1 Company overview
12.10.2 Financial overview
12.10.3 Strategic overview
12.10.3.1 Large investment in research and development
12.10.3.2 Global expansion through partnership
12.10.4 Recent developments
12.11 PolyPeptide Group.
12.11.1 Company overview
12.11.2 Strategic overview
12.11.2.1 Focus on product portfolio extension and quality product development
12.11.2.2 Global expansion through merger and acquisition
12.12 Amylin Pharmaceuticals LLC - Bristol-Myers Squibb (BMS)
12.12.1 Company overview
12.12.2 Amylin Pharmaceuticals LLC
12.12.3 Financial overview
12.12.4 Strategic overview (Amylin Pharmaceuticals LLC)
12.12.4.1 Entering into strategic collaborations
12.12.4.2 Corporate social responsibility
12.12.4.3 Rigorous R&D initiatives
12.12.5 Recent developments
12.13 AstraZeneca PLC
12.13.1 Company overview
12.13.2 Financial overview
12.13.3 Strategic overview
12.13.3.1 Rigorous R&D initiatives
12.13.3.2 Investing in emerging economies
12.13.4 Recent developments
12.14 Roche
12.14.1 Company overview
12.14.2 Financial overview
12.14.3 Strategic overview
12.14.3.1 Research and development initiatives
12.14.3.2 Focus on personalized healthcare
12.14.3.3 Focus on new and emerging markets
12.14.3.4 Funding awareness programs
12.14.4 Recent developments
12.15 GlaxoSmithKline (GSK)
12.15.1 Company overview
12.15.2 Financial overview
12.15.3 Strategic overview
12.15.3.1 Research and development initiatives
12.15.3.2 Direct to Consumer Advertising
12.15.3.3 Mergers and acquisitions
12.15.4 Recent developments
12.16 Merck & Co.
12.16.1 Company overview
12.16.2 Financial overview
12.16.3 Strategic overview
12.16.3.1 Corporate social responsibility
12.16.3.2 R&D Initiatives
12.16.3.3 Strategic alliances and out-licensing
12.16.4 Recent developments
12.17 Novartis AG
12.17.1 Company overview
12.17.2 Financial overview
12.17.3 Strategic overview
12.17.3.1 Mergers and acquisitions
12.17.3.2 Memorandum of understanding
12.17.4 Recent developments
12.18 Novo-Nordisk A/S
12.18.1 Company overview
12.18.2 Financial overview
12.18.3 Strategic overview
12.18.3.1 Partnerships and alliances
12.18.4 Agreements
12.18.5 Recent developments

List of Tables


TABLE 1 Global therapeutic peptides market: Snapshot 22
TABLE 2 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million) 23
TABLE 3 Global scenario of acquisitions of biotech firms by large pharma giants 31
TABLE 4 Major peptide drugs and sales, 2011 (USD Million) 31
TABLE 5 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million) 36
TABLE 6 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018 (USD Million) 56
TABLE 7 Methods of delivery for peptide drugs 57
TABLE 8 Global peptide therapeutics market, revenues, by types 2010 - 2018 (USD million) 63
TABLE 9 Global API peptide therapeutics Market, By Revenue, by Types, 2010 - 2018 (USD million) 67
TABLE 10 Global peptide therapeutics market revenues, by technology, 2010 - 2018 (USD Million) 70
TABLE 11 Global Peptide Therapeutics Market, By Geography, 2010-2018 (USD Million) 75

List of Figures


FIG. 1 Global Peptide Therapeutics: Market Snapshot 18
FIG. 2 Global peptide therapeutics market, by revenue, 2010 – 2018 (USD Million) 23
FIG. 3 Global API peptide therapeutics market, 2011 (USD Million) 24
FIG. 4 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%) 25
FIG. 5 Global peptide therapeutics trials growth, 1970 - 2011 27
FIG. 6 Porter’s five forces analysis for global peptide therapeutics market 32
FIG. 7 Market attractiveness analysis of the global peptide therapeutics market, by geography 34
FIG. 8 Global Cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 38
FIG. 9 Global cancer peptide therapeutics market revenues, 2010 - 2018 (USD Million) 39
FIG. 10 Global metabolic peptide therapeutics pipeline drugs analysis , number of trials, 2009 - 2012 40
FIG. 11 Global metabolic peptide therapeutics market revenues, 2010 - 2018 (USD Million) 40
FIG. 12 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 41
FIG. 13 Global cardiovascular peptide therapeutics market revenues, 2010 - 2018 (USD Million) 42
FIG. 14 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012 43
FIG. 15 Global dermatology peptides market revenues, 2010 - 2018 (USD Million) 44
FIG. 16 Global anti-infection pipeline drugs analysis, number of trials, 2009 - 2012 45
FIG. 17 Global anti-infection peptides market revenues, 2010 - 2018 (USD Million) 46
FIG. 18 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012 47
FIG. 19 Global neurology peptides market revenues, 2010 - 2018 (USD Million) 47
FIG. 20 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012 48
FIG. 21 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million) 49
FIG. 22 Global renal pipeline drugs analysis, number of trials, 2009 - 2012 50
FIG. 23 Global renal peptides market revenues, 2010 - 2018 (USD Million) 50
FIG. 24 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012 51
FIG. 25 Global respiratory peptides market, revenues, 2010 - 2018 (USD Million) 52
FIG. 26 Global pain pipeline drugs analysis, number of trials, 2009 - 2012 53
FIG. 27 Global pain peptides market revenues, 2010 - 2018 (USD Million) 53
FIG. 28 Global others pipeline drugs analysis, number of trials, 2009 - 2012 54
FIG. 29 Global others peptides market revenues, 2010 - 2018 (USD Million) 55
FIG. 30 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million) 58
FIG. 31 Global peptide therapeutics market revenues, by oral route of administration, 2010 - 2018 (USD Million) 59
FIG. 32 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million) 60
FIG. 33 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million) 61
FIG. 34 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million) 62
FIG. 35 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million) 65
FIG. 36 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million) 66
FIG. 37 Global API peptide therapeutics in-house market revenues, 2010 - 2018 (USD Million) 68
FIG. 38 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million) 69
FIG. 39 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million) 71
FIG. 40 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million) 72
FIG. 41 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million) 73
FIG. 42 Global peptide therapeutics market, by geography, 2011 - 2018 74
FIG. 43 North America peptide therapeutics market revenues, 2010 - 2018 (USD Million) 76
FIG. 44 Europe peptide therapeutics market revenues, 2010 - 2018 (USD Million) 77
FIG. 45 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million) 78
FIG. 46 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million) 79
FIG. 47 Global peptide therapeutics market share analysis of key players, 2011 (%) 81
FIG. 48 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%) 82
FIG. 49 Bachem Holding AG: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 87
FIG. 50 Eli Lilly & Company: annual revenues, 2009 – 2011 (USD Million) 89
FIG. 51 Pfizer, Inc.: annual revenues, 2009 – 2011 (USD Million) 91
FIG. 52 Amgen, Inc.: annual revenues, 2009 – 2011 (USD Million) 94
FIG. 53 Takeda Pharmaceutical Company Ltd.: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 JPY = 0.01 USD) 97
FIG. 54 Teva Pharmaceuticals: annual revenues, 2009 – 2011 (USD Million) 99
FIG. 55 Lonza Inc.: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 101
FIG. 56 Solvay Group: annual revenues, 2010 – 2011 (USD Million) (conversion rate: 1 Euro = 1.34 USD) 103
FIG. 57 Sanofi: annual revenues, 2009 – 2011 (USD Million) 105
FIG. 58 Ipsen: annual revenue Share, by geography, 2010 & 2011 (%) 107
FIG. 59 Ipsen: annual revenues, 2009 - 2011 (USD Million) 108
FIG. 60 Bristol-Myers Squibb: annual revenues, 2009 – 2011 (USD Million) 112
FIG. 61 AstraZaneca PLC: annual revenues, 2009 – 2011 (USD Million) 114
FIG. 62 Roche: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 116
FIG. 63 GSK: annual revenues, 2009 – 2011 (USD million) (conversion rate: 1 GBP = 1.5849 USD) 118
FIG. 64 Merck & Co.: annual revenues, 2009 – 2011 (USD Million) 120
FIG. 65 Novartis AG: annual revenues, 2009 – 2011 (USD Million) 123

Upcoming Reports:

Organ Transplant Immunosuppressant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Organ transplant immunosuppressants are a class of drugsadministered to lower the chances of organ rejection after a transplant and are also called as anti-rejection drugs. When a person gets an organ transplant such as kidney, liver or heart, the body identifies transplant as a foreign tissue and attacks it causing severe rejection. These immunosuppressant drugs weaken the immune system thereby decreasing the body’s reaction totransplant. Almost every person undergoing a solid organ transplant requires to take immunosuppressant drugs. Therefore the global market for these drugs is...
Poland: metal cans market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the metal cans market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the metal cans market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...
Greece: market of cement, concrete or artificial stone pipes
By - Williams and Marshal Strategy
udes: Analysis and dynamics of the economy of Greece; Forecast for the development of the economy of Greece; Analysis and forecast of market volume and dynamics; Volume, dynamics and analysis of domestic production; Characteristics of market structure (by origin, by types of products, etc.); Analysis of price level and dynamics; Volume, dynamics and analysis of imports; Volume, dynamics and analysis of exports; Volume, dynamics and analysis of consumption; Characteristics of the main market participants (manufacturers, importers and exporters); Analysis of the factors,...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Evereadys Kenya Plant to be Shut Down
Sep 30, 2014  
The largest dry-cell battery manufacturer in the region of East Africa, Eveready East Africa Ltd. intends on shutting down its one and only factory in Kenya on the 1st of October 2014. A real estate business will be started in its place. According to the Managing Director of Eveready East Africa Ltd. the plan of shutting down the plant was initiated by the board members of this company...
Sale of Apples iPhones Remains Unaffected - Supported By Consumer Feedback
Sep 29, 2014  
iPhones have been reintroduced in the global market by Apple Inc. in about 22 countries. Consumer reports and feedback basically show that due to the presence of a problem-free backing and update, these handsets are sturdy and do not bend easily. It has been observed via stress tests conducted on iPhone 6 and 6 Plus, that it requires high force and pressure to cause damage to these...
New Malware Targets Pharma Servers
Sep 29, 2014  
The electronics and communication agency Beldon has reportedly spotted a new cyber threat to the pharmaceutical industry. Called Dragonfly, the malware specifically targets intellectual property of servers in the pharmaceutical industry with the purpose of stealing information. An initial report released by ipprolifesciences.com stated the malware was targeting the energy sector....
Child’s Success Depends on Father’s Education Level: Study
Sep 24, 2014  
A father’s level of education is the strongest attribute that can determine a child’s success in academics, according to a research conducted in Britain. It also says that there is a self-reinforcing cycle of lack of achievement and poverty that is handed down from parent to child. The report was released by the Office for National Statistics and states that children are...
Orange Business Services to Extend into Internet Services
Sep 23, 2014  
Orange Business Services is set to create a business-class Internet service by extending its core VPN Business Service into VPN Business Internet. The move has been made to meet the increasing demand from multinational companies for a heavy-duty, high-performance, and secure access to Cloud and Web services on the Internet. It is the cornerstone Business VPN Internet by the Hybrid...